Use access key #2 to skip to page content.
$5.15 0.02 (0.39%)
7/23/2008 4:00 PM

BioSante Pharmaceuticals, Inc. (BPAX)

CAPS Rating:
**

A biopharmaceutical company that licenses and develops hormone therapy products to treat men and women.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating BPAX

Add Stock to Watchlist

What the Community Thinks

Total Members

78 Outperforms
14 Underperforms
 

All-Stars

17 Outperforms
9 Underperforms
 

Wall Street

1 Outperforms
0 Underperforms
 

Members bullish on BPAX are also bullish on:

Members bearish on BPAX are also bearish on:

Ticker Tags

Biotechnology (294), Rule Breakers Universe (161), Micro Cap (4824), Nanotechnology (29)
Suggest a tag

BioSante Pharmaceuticals, Inc. At A Glance

Current Price: $5.15
Last Trade Time: 7/23/2008 4:00 PM
Open: $0.00
Previous Close: $5.13
Daily Range: $5.05 - $5.21
52-Week Range: $2.05 - $5.86
Volume: 86,510
Market Cap: $137.48M
P/E Ratio: 11.26
Compare Our Special Broker Offers!

Stock Trends

BPAX VS S&P 500 (SPY)

BPAX 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for BPAX

More Headlines...

Top Bull Pitch

Recs

1

BioSante Pharmaceuticals, Inc. (BPAX)

Avatar tibber61 (84.08) Submitted: 3/28/07 9:28 PM

Unlike most bio firms, tech research companies focused on delivery systems seem to yield larger "hits" than "misses" by applying their discoveries over broader markets; most traditional biotechs seem to have too narrow a focus, leading to significant company impact when trials fail.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

2

BioSante Pharmaceuticals, Inc. (BPAX)

Avatar tweakie (< 20) Submitted: 2/05/08 2:46 AM

Why the heck did the CEO write to Adam Feuerstein??? Poor leadership.

Replies: 1 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 18 :   1 2 3 4 Next »

Recs

0

 (BPAX)

Avatar pranilbalram (68.74) Submitted: 6/19/08 4:21 PM : Outperform Start Price: $5.45 BPAX Score: -1.92

Nice pipeline of products and exhibits the potential for a buyout. Very high debt ratio so the risk is high, however, strong working capital is present.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BPAX)

Avatar KBroodie1 (67.36) Submitted: 6/13/08 11:28 AM : Outperform Start Price: $5.60 BPAX Score: -2.38

They will improve overtime

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BPAX)

Avatar Derrickmarshall (< 20) Submitted: 6/11/08 12:46 AM : Outperform Start Price: $4.31 BPAX Score: 25.53

Possible buyout target

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BPAX)

Avatar MikeNels2000 (45.02) Submitted: 5/24/08 3:54 PM : Outperform Start Price: $4.08 BPAX Score: 33.18

Viagra for women, Libigel could be a billion dollar drug if current phase III trial goals are met.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BPAX)

Avatar zzlangerhans (91.05) Submitted: 4/15/08 2:52 AM : Underperform Start Price: $4.02 BPAX Score: -32.06

I'm going to come down on the negative side on Biosante while the cap is still above 100M. Biosante basically has Elestrin and LibiGel. Elestrin was approved in 12/06 and doesn't seem to have generated any significant revenues whatsoever, a fact the company seems to be obfuscating in quarterly statements. LibiGel has been making progress, but even if all phase III trials are successful the CEO doesn't predict an NDA before 2010. That's a lot of time for Biosante stock to slide back down into the 60M cap it was occupying before the recent odd price bump. Toss in a liberal helping of snake oil salesmanship and historical shortcomings, and my skepticism is solid.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 18 :   1 2 3 4 Next »

Wall Street

Results 1 - 1 of 1  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackOppenheimer < 20 08/23/07 Outperform NS $5.65-8.85%-12.98%+4.13

Results 1 - 1 of 1  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners